Skip to main
DYN
DYN logo

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics (DYN) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 38%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Dyne Therapeutics Inc. is positioned favorably due to its innovative FORCE platform, which enhances the delivery of therapeutics specifically targeting genetically driven neuromuscular diseases. The company’s clinical pipeline, including candidates such as DYNE-101, DYNE-251, DYNE-302, and DYNE-401, underscores its commitment to addressing unmet medical needs in this niche market. Despite potential regulatory challenges and competitive risks, the strategic focus on developing life-transforming therapeutics provides a robust foundation for future growth and market presence.

Bears say

Dyne Therapeutics Inc faces significant challenges that contribute to a negative outlook on its stock. Key concerns include the potential erosion of pricing power due to heightened competition, including generics, and the risks associated with insufficient intellectual property protection, which could lead to increased competition and reduced revenue expectations. Moreover, as a clinical-stage company, Dyne may need to secure additional financing before achieving profitability, complicating its financial stability in a potentially unfavorable market environment.

Dyne Therapeutics (DYN) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 38% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dyne Therapeutics (DYN) Forecast

Analysts have given Dyne Therapeutics (DYN) a Buy based on their latest research and market trends.

According to 13 analysts, Dyne Therapeutics (DYN) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.77, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.77, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dyne Therapeutics (DYN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.